Edition:
United Kingdom

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

40.01USD
16 Feb 2018
Change (% chg)

$-0.61 (-1.50%)
Prev Close
$40.62
Open
$40.88
Day's High
$42.08
Day's Low
$39.50
Volume
192,042
Avg. Vol
167,132
52-wk High
$44.96
52-wk Low
$13.50

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2017 Sep '17 2.39 -0.616
Jun '17 3.58 -0.559
Mar '17 2.70 -0.541
FY 2016 Dec '16 2.34 1.395
Sep '16 1.55 -0.369
Jun '16 0.80 -0.432
Mar '16 0.48 -0.212
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Mar-18 3 2.97 4.40 0.50 4.00
Quarter Ending Jun-18 3 3.43 5.30 0.50 4.00
Year Ending Dec-18 5 14.04 24.00 2.00 7.46
Earnings (per share)
Quarter Ending Mar-18 4 -0.65 -0.56 -0.69 -0.48
Quarter Ending Jun-18 4 -0.68 -0.58 -0.74 -0.48
Year Ending Dec-18 6 -2.84 -2.38 -3.08 -2.79
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 83.93 32.90
P/E High - Last 5 Yrs. -- 292.71 45.97
P/E Low - Last 5 Yrs. -- 91.44 24.37
Beta -- 0.90 0.89
Price to Sales (TTM) 76.97 110.72 5.77
Price to Book (MRQ) 3.91 13.56 5.41
Price to Tangible Book (MRQ) 3.97 14.02 6.98
Price to Cash Flow (TTM) -- 71.33 23.42
% Owned Institutions 41.85 12.89 2.22

Dividends

  Company industry sector
Dividend Yield -- 0.31 1.50
Dividend Yield - 5 Year Avg -- 0.26 1.52
Dividend 5 Year Growth Rate -- 1.66 5.21
Payout Ratio(TTM) -- 15.70 43.72

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago 350.57 398.33 9.24
Sales (TTM) vs TTM 1 Yr. Ago 570.49 78.63 5.59
Sales - 5 Yr. Growth Rate -- 32.11 10.27
EPS (MRQ) vs Qtr. 1 Yr. Ago -29.58 25.10 19.65
EPS (TTM) vs TTM 1 Yr. Ago 93.32 -- --
EPS - 5 Yr. Growth Rate -- 38.95 10.73
Capital Spending - 5 Yr. Growth Rate -- 40.24 15.19

Financial Strength

  Company industry sector
Quick Ratio (MRQ) -- 1.80 2.18
Current Ratio (MRQ) 17.79 5.30 2.97
LT Debt to Equity (MRQ) 0.00 22.82 12.22
Total Debt to Equity (MRQ) 0.00 24.47 16.52
Interest Coverage (TTM) -5.27 -98.78 33.13

Profitability Ratios

  Company industry sector
Gross Margin (TTM) -- 40.03 54.70
Gross Margin - 5 Yr. Avg. -- 51.06 52.42
EBITD Margin (TTM) -784.99 -- --
EBITD - 5 Yr. Avg -- -572.68 10.86
Operating Margin (TTM) -805.36 -717.10 4.64
Operating Margin - 5 Yr. Avg. -- -594.00 6.26
Pre-Tax Margin (TTM) -396.50 -691.66 5.44
Pre-Tax Margin - 5 Yr. Avg. -- -597.35 6.60
Net Profit Margin (TTM) -406.62 -692.88 1.76
Net Profit Margin - 5 Yr. Avg. -- -600.21 2.91
Effective Tax Rate (TTM) -- 22.57 23.04
Effective Tax Rate - 5 Yr. Avg. -- 18.19 23.96

Efficiency

  Company industry sector
Revenue/Employee (TTM) 109,441 22,602,121 855,667,832
Net Income/Employee (TTM) -445,011 2,968,747 100,655,557
Receivable Turnover (TTM) 2.49 20.14 5.78
Inventory Turnover (TTM) -- 2.36 3.35
Asset Turnover (TTM) 0.03 0.39 0.93

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -13.84 -1.05 10.98
Return on Assets - 5 Yr. Avg. -- -0.57 12.37
Return on Investment (TTM) -16.50 1.66 14.43
Return on Investment - 5 Yr. Avg. -- 2.23 16.18
Return on Equity (TTM) -56.05 2.58 16.13
Return on Equity - 5 Yr. Avg. -- 3.13 17.47
  1 Year 3 Year 5 Year
Sales % 1,990.69 -- --
EPS (TTM) % -194.70 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for CRISPR Therapeutics AG

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week 2.99 -0.56 99 53
13 Week 21.54 15.62 99 62
26 Week 0.05 -7.55 99 77
52 Week -- -- -- 50
YTD -4.74 -16.34 79 56
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 43.49%
# of Holders: 93
Total Shares Held: 19,959,258
3 Mo. Net Change: 2,375,772
# New Positions: 40
# Closed Positions: 17
# Increased Positions: 63
# Reduced Positions: 27
# Net Buyers: 36
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.